Work

EP08.02-034 OCELOT - Osimertinib then Chemotherapy in EGFR+ Lung Cancer with Osi Third-line Rechallenge and Osimertinib for Uncommon EGFRm in 1L

Year: 2022

Type: conference-abstract

Source: Journal of Thoracic Oncology

DOI: 10.1016/j.jtho.2022.07.716

Authors: D. Breadner, G. Liu, J. Rothenstein, P. Wheatley-Price, P. Bains, S. Cheng, Y. Wang, S. Sun, H. Mithoowani, R. Juergens, P. Cheema, M. Vincent

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4294941556

Cites:

Cited by:

Related to: 10